- Home
- OSUR vs LCTX Comparison
OSUR vs LCTX Comparison
Compare OSUR & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- LCTX
- Stock Information
- Founded
- OSUR 2000
- LCTX 1990
- Country
- OSUR United States
- LCTX United States
- Employees
- OSUR N/A
- LCTX N/A
- Industry
- OSUR Medical/Dental Instruments
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OSUR Health Care
- LCTX Health Care
- Exchange
- OSUR Nasdaq
- LCTX Nasdaq
- Market Cap
- OSUR 231.1M
- LCTX 274.0M
- IPO Year
- OSUR 1986
- LCTX N/A
- Fundamental
- Price
- OSUR $2.58
- LCTX $1.83
- Analyst Decision
- OSUR Hold
- LCTX Strong Buy
- Analyst Count
- OSUR 1
- LCTX 4
- Target Price
- OSUR $3.00
- LCTX $4.25
- AVG Volume (30 Days)
- OSUR 464.4K
- LCTX 1.9M
- Earning Date
- OSUR 11-05-2025
- LCTX 11-06-2025
- Dividend Yield
- OSUR N/A
- LCTX N/A
- EPS Growth
- OSUR N/A
- LCTX N/A
- EPS
- OSUR N/A
- LCTX N/A
- Revenue
- OSUR $138,533,000.00
- LCTX $10,914,000.00
- Revenue This Year
- OSUR N/A
- LCTX N/A
- Revenue Next Year
- OSUR $4.32
- LCTX $176.00
- P/E Ratio
- OSUR N/A
- LCTX N/A
- Revenue Growth
- OSUR N/A
- LCTX 76.43
- 52 Week Low
- OSUR $2.36
- LCTX $0.37
- 52 Week High
- OSUR $4.60
- LCTX $2.08
- Technical
- Relative Strength Index (RSI)
- OSUR 27.36
- LCTX 58.80
- Support Level
- OSUR $2.86
- LCTX $1.66
- Resistance Level
- OSUR $3.00
- LCTX $2.09
- Average True Range (ATR)
- OSUR 0.10
- LCTX 0.12
- MACD
- OSUR -0.03
- LCTX 0.01
- Stochastic Oscillator
- OSUR 0.89
- LCTX 52.68
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.